国内头部药企持续迎来积极进展。当科学创新撞上监管铁幕,这就是昔日疫苗新贵Moderna,正在面临的前所未有局面。不久前,Moderna宣布撤回其新冠/流感双价疫苗mRNA-1083的上市申请,这一决定让其股价单日大跌近8%,如果拉长周期来看,Moderna股价在一路下挫中,几乎重回疫情之前。撤回背后,表面是FDA监管框架的突变,从“免疫原性优势”到“全人群有效性验证”的转向,让Moderna不得不...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.